{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:14:50Z","timestamp":1794953690250,"version":"4.9.1"},"reference-count":106,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite advancements, acute myeloid leukemia (AML) remains unconquered by current therapies. Evidence of immune evasion during AML progression, such as HLA loss and T-cell exhaustion, suggests that antileukemic immune responses contribute to disease control and could be harnessed by immunotherapy. In this review, we discuss a spectrum of AML immunotherapy targets, encompassing cancer cell-intrinsic and surface antigens as well as targeting in the leukemic milieu, and how they can be tailored for personalized approaches. These targets are overviewed across major immunotherapy modalities applied to AML: immune checkpoint inhibitors, antibody\u2013drug conjugates, therapeutic vaccines, bispecific\/trispecific antibodies, and chimeric antigen receptor (CAR)-T and CAR-NK cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Immune therapies in AML treatment show evolving promise. Ongoing research aims to customize approaches for varied patient profiles and clinical scenarios. This review covers immune surveillance mechanisms, therapy options like checkpoint inhibitors, antibodies, CAR-T\/NK cells, and vaccines, as well as resistance mechanisms and microenvironment considerations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0202","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:59:31Z","timestamp":1718956771000},"page":"234-248","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-4842","authenticated-orcid":false,"given":"Cecilia","family":"Restelli","sequence":"first","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA. 3"},{"name":"Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA. 3"},{"name":"Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-6046","authenticated-orcid":false,"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-2316","authenticated-orcid":false,"given":"Pier Giuseppe","family":"Pelicci","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy. 1"},{"name":"Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-7398","authenticated-orcid":false,"given":"Emanuela","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy. 1"},{"name":"Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2026041310133509800_bib1","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041310133509800_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tcb.2019.01.003","article-title":"Mutational and antigenic landscape in tumor progression and cancer immunotherapy","volume":"29","author":"Vitale","year":"2019","journal-title":"Trends Cell Biol"},{"key":"2026041310133509800_bib3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"2026041310133509800_bib4","first-page":"1","article-title":"Contemporary approach to acute myeloid leukemia therapy in 2022","volume":"42","author":"Roloff","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026041310133509800_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/leu.2011.224","article-title":"Commentary: does immune suppression increase risk of developing acute myeloid leukemia?","volume":"26","author":"Gale","year":"2012","journal-title":"Leukemia"},{"key":"2026041310133509800_bib6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"2026041310133509800_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2026041310133509800_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"2026041310133509800_bib9","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"2026041310133509800_bib10","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041310133509800_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/bloodadvances.2022008863","article-title":"Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT","volume":"7","author":"Olsen","year":"2023","journal-title":"Blood Adv"},{"key":"2026041310133509800_bib12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","article-title":"Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells","volume":"4","author":"Nelde","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026041310133509800_bib13","doi-asserted-by":"crossref","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"2026041310133509800_bib14","doi-asserted-by":"crossref","first-page":"e159579","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Invest"},{"key":"2026041310133509800_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026041310133509800_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"2026041310133509800_bib17","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026041310133509800_bib18","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"2026041310133509800_bib19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"2026041310133509800_bib20","doi-asserted-by":"crossref","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis","volume":"12","author":"G\u00f3mez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"2026041310133509800_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"2026041310133509800_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"2026041310133509800_bib23","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","article-title":"AML-484 first results of a phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310133509800_bib24","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","article-title":"Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy","volume":"5","author":"Abbas","year":"2021","journal-title":"Blood Adv"},{"key":"2026041310133509800_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041310133509800_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-021-00453-z","article-title":"Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study","volume":"11","author":"Reville","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"2026041310133509800_bib27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1182\/blood-2022-157326","article-title":"Randomized phase II study to assess the role of nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (NCI9706 protocol; REMAIN trial)","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310133509800_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"2026041310133509800_bib29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"2026041310133509800_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310133509800_bib31","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.2022017686","article-title":"Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings","volume":"141","author":"Garcia","year":"2023","journal-title":"Blood"},{"key":"2026041310133509800_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clml.2021.01.010","article-title":"Evaluating predictors of immune-related adverse events and response to checkpoint inhibitors in myeloid malignancies","volume":"21","author":"Gesiotto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310133509800_bib33","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells","volume":"236","author":"Wang","year":"2021","journal-title":"J Cell Physiol"},{"key":"2026041310133509800_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"2026041310133509800_bib35","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310133509800_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2026041310133509800_bib37","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2022015474","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post\u2013allo-HSCT","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2026041310133509800_bib38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41598-022-05470-x","article-title":"Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)","volume":"12","author":"Allende-Vega","year":"2022","journal-title":"Sci Rep"},{"key":"2026041310133509800_bib39","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"key":"2026041310133509800_bib40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2026041310133509800_bib41","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1002\/cam4.3360","article-title":"Immunosuppressive role of CD11b+ CD33+ HLA-DR\u2212 myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia","volume":"9","author":"Hyun","year":"2020","journal-title":"Cancer Med"},{"key":"2026041310133509800_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026041310133509800_bib43","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol Ther"},{"key":"2026041310133509800_bib44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/s41375-019-0394-z","article-title":"The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells","volume":"33","author":"Zhang","year":"2019","journal-title":"Leukemia"},{"key":"2026041310133509800_bib45","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-01-624163","article-title":"In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity","volume":"126","author":"Messmann","year":"2015","journal-title":"Blood"},{"key":"2026041310133509800_bib46","doi-asserted-by":"crossref","first-page":"790299","DOI":"10.3389\/fonc.2021.790299","article-title":"Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol"},{"key":"2026041310133509800_bib47","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026041310133509800_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"2026041310133509800_bib49","doi-asserted-by":"crossref","first-page":"787108","DOI":"10.3389\/fonc.2022.787108","article-title":"Antigen-specific TCR-T cells for acute myeloid leukemia: state of the art and challenges","volume":"12","author":"Kang","year":"2022","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"2026041310133509800_bib50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2019-128044","article-title":"A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation","volume":"134","author":"Morris","year":"2019","journal-title":"Blood"},{"key":"2026041310133509800_bib51","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2026041310133509800_bib52","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2023-187355","article-title":"Initial results of a phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to prevent relapse after allogeneic hematopoietic cell transplantation","volume":"142","author":"Al Malki","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310133509800_bib53","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"2026041310133509800_bib54","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"2026041310133509800_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026041310133509800_bib56","doi-asserted-by":"crossref","first-page":"101695","DOI":"10.1016\/j.tranon.2023.101695","article-title":"Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape","volume":"34","author":"Xie","year":"2023","journal-title":"Transl Oncol"},{"key":"2026041310133509800_bib57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026041310133509800_bib58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"2026041310133509800_bib59","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"2026041310133509800_bib60","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"key":"2026041310133509800_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"key":"2026041310133509800_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026041310133509800_bib63","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1021\/acs.molpharmaceut.2c00913","article-title":"Anti-acute myeloid leukemia activity of CD38-CAR-T cells with PI3K\u03b4 downregulation","volume":"20","author":"An","year":"2023","journal-title":"Mol Pharm"},{"key":"2026041310133509800_bib64","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026041310133509800_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm8020200","article-title":"Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J Clin Med"},{"key":"2026041310133509800_bib66","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"2026041310133509800_bib67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041310133509800_bib68","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"2026041310133509800_bib69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cancers16020334","article-title":"CD45-Directed CAR-T cells with CD45 knockout efficiently kill myeloid leukemia and lymphoma cells in vitro even after extended culture","volume":"16","author":"Harfmann","year":"2024","journal-title":"Cancers Basel"},{"key":"2026041310133509800_bib70","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"2026041310133509800_bib71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026041310133509800_bib72","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310133509800_bib73","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"2026041310133509800_bib74","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1158\/1538-7445.AM2023-3201","article-title":"Abstract 3201: CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia","volume":"83","author":"Garner","year":"2023","journal-title":"Cancer Res"},{"key":"2026041310133509800_bib75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol"},{"key":"2026041310133509800_bib76","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026041310133509800_bib77","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/cancers13112673","article-title":"Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor","volume":"13","author":"Devillier","year":"2021","journal-title":"Cancers Basel"},{"key":"2026041310133509800_bib78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bjh.18469","article-title":"Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers","volume":"200","author":"Circosta","year":"2023","journal-title":"Br J Haematol"},{"key":"2026041310133509800_bib79","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026041310133509800_bib80","doi-asserted-by":"crossref","first-page":"1112059","DOI":"10.3389\/fimmu.2023.1112059","article-title":"NK cell defects: implication in acute myeloid leukemia","volume":"14","author":"D\u2019Silva","year":"2023","journal-title":"Front Immunol"},{"key":"2026041310133509800_bib81","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041310133509800_bib82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026041310133509800_bib83","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"2026041310133509800_bib84","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"2026041310133509800_bib85","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041310133509800_bib86","doi-asserted-by":"crossref","first-page":"20406207231154708","DOI":"10.1177\/20406207231154708","article-title":"Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia","volume":"14","author":"Swaminathan","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"2026041310133509800_bib87","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"key":"2026041310133509800_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-137218","article-title":"A phase I study of lintuzumab Ac225 in combination with CLAG-M chemotherapy in relapsed\/refractory AML","volume":"136","author":"Abedin","year":"2020","journal-title":"Blood"},{"key":"2026041310133509800_bib89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"2026041310133509800_bib90","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"2026041310133509800_bib91","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2019-128501","article-title":"A phase 1b\/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and\/or azacitidine for patients with CD123-positive acute myeloid leukemia","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310133509800_bib92","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2019-128648","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"2026041310133509800_bib93","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/01.HS9.0000850164.28901.b2","article-title":"PB1828: Cadenza: a pivotal study of pivekimab sunirine (IMGN632) in patients with untreated\/frontline BPDCN","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Hemasphere"},{"key":"2026041310133509800_bib94","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"2026041310133509800_bib95","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","volume":"105","author":"Vo","year":"2020","journal-title":"Haematologica"},{"key":"2026041310133509800_bib96","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"2026041310133509800_bib97","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"2026041310133509800_bib98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life Basel"},{"key":"2026041310133509800_bib99","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041310133509800_bib100","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00262-021-03008-0","article-title":"CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026041310133509800_bib101","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/jcm8050579","article-title":"Dendritic cell-based immunotherapy of acute myeloid leukemia","volume":"8","author":"Van Acker","year":"2019","journal-title":"J Clin Med"},{"key":"2026041310133509800_bib102","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2026041310133509800_bib103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2026041310133509800_bib104","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15818","article-title":"Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine","volume":"185","author":"Nahas","year":"2019","journal-title":"Br J Haematol"},{"key":"2026041310133509800_bib105","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.vaccine.2020.03.042","article-title":"Whole leukemia cell vaccines: past progress and future directions","volume":"38","author":"Ji","year":"2020","journal-title":"Vaccine"},{"key":"2026041310133509800_bib106","doi-asserted-by":"crossref","first-page":"697964","DOI":"10.3389\/fimmu.2021.697964","article-title":"Immunogenic cell death-based cancer vaccines","volume":"12","author":"Jin","year":"2021","journal-title":"Front Immunol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0202\/3464357\/bcd-23-0202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/234\/3470396\/bcd-23-0202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/234\/3470396\/bcd-23-0202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:13:57Z","timestamp":1776089637000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/4\/234\/746106\/Recent-Advances-in-Immune-Based-Therapies-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":106,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,21]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0202","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}